Table1_Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking.DOCX
Background: By improving the affordability and accessibility of biologicals, biosimilar competition provides important benefits to healthcare systems and patients. In Belgium, biosimilar uptake and competition is limited compared to other European markets. Whereas other countries have initiated structured biosimilar introduction or switching plans, no such framework or guiding principles are yet available in Belgium. Objective: This study aims to develop recommendations that can inform policy action in Belgium on biosimilar use, especially in the context of switch decision-making, and this by... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Dataset |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Pharmacology / Basic Pharmacology / Clinical Pharmacology and Therapeutics / Clinical Pharmacy and Pharmacy Practice / Pharmaceutical Sciences / Pharmacogenomics / Toxicology (incl. Clinical Toxicology) / Pharmacology and Pharmaceutical Sciences not elsewhere classified / biosimilar / biological / best-value biological / switching / stakeholder incentives / healthcare professional / policy making |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-28564733 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3389/fphar.2022.821616.s001 |